Crinetics Pharmaceuticals Inc. (6Z4)

Overview

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is deeply engaged in the discovery, development, and eventual commercialization of innovative therapeutics targeting rare endocrine disorders and endocrine-related tumors. Founded in 2008, Crinetics has established its headquarters in the critical biotech hub of San Diego, California. The company leverages its expertise to address unmet medical needs in the endocrine field, focusing on conditions that are often overlooked but significantly impact patient quality of life.

Products and Services

• Paltusotine:

An oral selective nonpeptide somatostatin receptor type 2 agonist, Paltusotine is Crinetics' flagship product candidate. It is currently undergoing a Phase 3 clinical trial for acromegaly, a hormonal disorder that results from an excess of growth hormone, and a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. This demonstrates the company's dedication to finding effective treatments for complex endocrine diseases.

• CRN04894:

This investigational oral nonpeptide product candidate aims to antagonize the adrenocorticotrophic hormone (ACTH) receptor. Having completed a Phase 1 study, CRN04894 is designed to treat diseases caused by excess ACTH, such as congenital adrenal hyperplasia and Cushing's disease, highlighting Crinetics' pursuit of solutions for adrenal gland disorders.

• PTH Receptor Antagonists:

These compounds are being developed to target the parathyroid hormone (PTH) receptor, for the treatment of conditions such as primary hyperparathyroidism and humoral hypercalcemia of malignancy. By focusing on diseases of excess PTH, Crinetics aims to address the significant challenges faced by patients with these rare disorders.

• Orally Available Somatostatin Receptor Type 3 Targeted Nonpeptide Agonists:

Crinetics is researching these compounds for the potential treatment of autosomal dominant polycystic kidney disease, a genetic disorder affecting the kidneys. This reflects the company's commitment to exploring applications of its technology across a range of endocrine and related diseases.

• Thyroid-Stimulating Hormone Receptor Antagonists:

Developed for the treatment of Graves' disease and thyroid eye disease, these antagonists target the thyroid-stimulating hormone receptor, addressing critical needs in managing thyroid health and associated conditions.

• Oral GLP-1 and GIP Nonpeptides:

Targeting diabetes and obesity, these products represent Crinetics' expansion into metabolic disorders, utilizing its endocrine expertise to develop treatments that address widespread health issues beyond rare diseases.